
Humana (HUM) Stock Forecast & Price Target
Humana (HUM) Analyst Ratings
Bulls say
Humana's increased 2025 earnings per share (EPS) estimate to $17.06 reflects strong second-quarter results and revised guidance, indicating a positive financial trajectory. The company's focus on margin initiatives is expected to drive year-over-year earnings growth in 2027, despite a stable star rating assumption for that year. Additionally, Humana's above-industry Medicare Advantage star rating positions it competitively, particularly in light of evolving regulatory and reimbursement conditions, providing a robust foundation for future performance.
Bears say
Humana's financial outlook is challenged by expected declines in earnings per share (EPS) for 2026, primarily due to headwinds related to MA Stars ratings and the anticipation of increased competition in the Medicare Advantage (MA) sector. Furthermore, the company faces additional downside risks including inadequate reimbursement rates, a reduction in PDP membership, and slower growth in its Healthcare Services division, which collectively threaten future profitability. For FY27, the potential shortfall of approximately 10% in EPS estimates highlights the impact of necessary investments aimed at recovering MA Stars ratings, indicating ongoing financial pressures.
This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares